CoChat
Sign Up
Cited by 221

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach

Mahmoodi Chalbatani, Ghanbar, Dana, Hassan, Gharagouzloo, Elahe, Grijalvo, Santiago, Eritja, Ramon, Logsdon, Craig D., Memari, Fereydon, Miri, Seyed Rohollah, Rezvani Rad, Mahdi, Marmari, Vahid·2019·International Journal of Nanomedicine
DOI 10.2147/ijn.s200253PMC PMC6504672
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ijn.s200253

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mechanism of action of siRNA molecules. SiRNA duplexes are incorporated in the RNA-induced silencing complex (RISC). Then, siRNA are unwinded and the strand with lower thermodynamic stability at its 5’end remains in the complex and guides it to the complementary mRNA. The target mRNA is then cleaved and protein expression is abolished or reduced.
Figure 1 Mechanism of action of siRNA molecules. SiRNA duplexes are incorporated in the RNA-induced silencing complex (RISC). Then, siRNA are unwinded and the strand with lower thermodynamic stability at its 5’end remains in the complex and guides it to the complementary mRNA. The target mRNA is then cleaved and protein expression is abolished or reduced.CC BY-NC · PubMed Central
Figure 2 A schematic image of LNPs siRNA showing a nanostructured core.
Figure 2 A schematic image of LNPs siRNA showing a nanostructured core.CC BY-NC · PubMed Central
Figure 3 A schematic representation of several strategies for encapsulating siRNA in liposomes.
Figure 3 A schematic representation of several strategies for encapsulating siRNA in liposomes.CC BY-NC · PubMed Central
Figure 4 Schematic illustration of a Cyclodextrin structure.
Figure 4 Schematic illustration of a Cyclodextrin structure.CC BY-NC · PubMed Central
Figure 5 A schematic representation of a dendrimer showing the central core, the peripherical sites, and the consecutive generations.
Figure 5 A schematic representation of a dendrimer showing the central core, the peripherical sites, and the consecutive generations.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 170

  1. [1]Ebrahimi M, Moazzen F, Marmari V, et al. In silico analysis, cloning and expression of recombinant CD166 in E. coli BL21 (DE3) as a marker for detection and treatment of colorectal cancer. J Med Microbiol Diagnosis. 2017; 06(01): 1– 6. doi: 10.4172/2161-0703.1000249 · DOI
  2. [2]Vries RGJ, Huch M, Clevers H. Stem cells and cancer of the stomach and intestine. Mol Oncol. 2010; 4(5): 373– 384. doi: 10.1016/j.molonc.2010.05.001 20598659 PMC5527927 · DOI
  3. [3]Dana H. An overview of cancer stem cell. J Stem Cell Res Ther. 2017; 1(4): 169– 174. doi: 10.15406/jsrt.2016.01.00029 · DOI
  4. [4]Zhang X, Li X, You Q, Zhang X. Prodrug strategy for cancer cell-specific targeting: a recent overview. Eur J Med Chem. 2017; 139: 542– 563. doi: 10.1016/j.ejmech.2017.08.010 28837920 · DOI
  5. [5]Hassanpour SH, Dehghani M. Review of cancer from perspective of molecular. J Cancer Res Pract. 2017; 4(4): 127– 129. doi: 10.1016/j.jcrpr.2017.07.001 · DOI
  6. [6]Saraswathy M, Gong S. Recent developments in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment. Mater Today. 2014; 17(6): 298– 306. doi: 10.1016/j.mattod.2014.05.002 · DOI
  7. [8]Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1): 9– 29. doi: 10.3322/caac.21208 24399786 · DOI · Paper page
  8. [9]Spano J-P, Azria D, Gonçalves A. Patients’ satisfaction in early breast cancer treatment: change in treatment over time and impact of HER2-targeted therapy. Crit Rev Oncol Hematol. 2015; 94(3): 270– 278. doi: 10.1016/j.critrevonc.2015.01.007 25682223 · DOI
  9. [10]Wee Gan C, Chien S, Feng -S-S. Nanomedicine: enhancement of chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle formulation. Curr Pharm Des. 2010; 16(21): 2308– 2320. doi: 10.2174/138161210791920487 20618152 · DOI
  10. [11]Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2013; 6(1): 34– 45. doi: 10.4161/mabs.27022 PMC3929453 24423619 · DOI
  11. [12]Leal M, Sapra P, Hurvitz SA, et al. Antibody–drug conjugates: an emerging modality for the treatment of cancer. Ann N Y Acad Sci. 2014; 1321(1): 41– 54. doi: 10.1111/nyas.12499 25123209 · DOI
  12. [13]Jain S, Pathak K, Vaidya A. Molecular therapy using siRNA: recent trends and advances of multi target inhibition of cancer growth. Int J Biol Macromol. 2018; 116: 880– 892. doi: 10.1016/j.ijbiomac.2018.05.077 29782974 · DOI
  13. [14]Mahmoodzad H, Ardaneh M, Zeinalinia E, et al. Microrna a new gate in cancer and human disease: a review. J Biol Sci. 2017; 17(6): 247– 254. doi: 10.3923/jbs.2017.247.254 · DOI
  14. [16]Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci. 2001; 98(17): 9742– 9747. doi: 10.1073/pnas.171251798 11481446 PMC55523 · DOI
  15. [17]Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411(6836): 494– 498. doi: 10.1038/35078107 11373684 · DOI · Paper page
  16. [18]Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007; 8(3): 173– 184. doi: 10.1038/nrg2006 17304245 · DOI · Paper page
  17. [19]Dana H, Chalbatani GM, Mahmoodzadeh H, et al. Molecular mechanisms and biological functions of siRNA. Int J Biomed Sci. 2017; 13(2): 48– 57. 28824341 PMC5542916
  18. [20]Yang J. Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis. Expert Rev Clin Pharmacol. 2019; 12(2): 95– 99. doi: 10.1080/17512433.2019.1567326 30644768 · DOI
  19. [22]Hong CA, Nam YS. Functional nanostructures for effective delivery of small interfering RNA therapeutics. Theranostics. 2014; 4(12): 1211– 1232. doi: 10.7150/thno.8491 25285170 PMC4183999 · DOI
  20. [23]Lee S-Y, Lee SJ, Oh Y-K, et al. Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing. J Control Release. 2009; 141(3): 339– 346. doi: 10.1016/j.jconrel.2009.10.007 19836427 · DOI
  21. [24]Sjouke B, Balak DMW, Beuers U, Ratziu V, Stroes ESG. Is mipomersen ready for clinical implementation? A transatlantic dilemma. Curr Opin Lipidol. 2013; 24: 4. doi: 10.1097/MOL.0b013e328362dfd9 23759796 · DOI
  22. [25]Burnett J, Rossi J. RNA-based therapeutics: current progress and future prospects. Chem Biol. 2012; 19(1): 60– 71. doi: 10.1016/j.chembiol.2011.12.008 22284355 PMC3269031 · DOI · Paper page
  23. [26]Biswas S, Deshpande PP, Navarro G, Dodwadkar NS, Torchilin VP. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials. 2013; 34(4): 1289– 1301. doi: 10.1016/j.biomaterials.2012.10.024 23137395 PMC3511617 · DOI
  24. [28]Rettig GR, Behlke MA. Progress toward in vivo use of siRNAs-II. Mol Ther. 2012; 20(3): 483– 512. doi: 10.1038/mt.2011.263 22186795 PMC3293614 · DOI
  25. [29]Tsunoda S, Mazda O, Oda Y, et al. Sonoporation using microbubble BR14 promotes pDNA/siRNA transduction to murine heart. Biochem Biophys Res Commun. 2005; 336(1): 118– 127. doi: 10.1016/j.bbrc.2005.08.052 16125678 · DOI
  26. [30]Kishida T, Asada H, Gojo S, et al. Sequence-specific gene silencing in murine muscle induced by electroporation-mediated transfer of short interfering RNA. J Gene Med. 2004; 6(1): 105– 110. doi: 10.1002/jgm.456 14716682 · DOI
  27. [31]Morrissey DV, Blanchard K, Shaw L, et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology. 2005; 41(6): 1349– 1356. doi: 10.1002/hep.20702 15880588 · DOI
  28. [32]Zhang S, Zhao B, Jiang H, Wang B, Ma B. Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release. 2007; 123(1): 1– 10. doi: 10.1016/j.jconrel.2007.07.016 17716771 · DOI
  29. [33]Kim WJ, Kim SW. Efficient siRNA delivery with non-viral polymeric vehicles. Pharm Res. 2009; 26(3): 657– 666. doi: 10.1007/s11095-008-9774-1 19015957 · DOI
  30. [34]Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release. 2007; 121(1–2): 64– 73. doi: 10.1016/j.jconrel.2007.05.021 17588702 · DOI
  31. [35]Tseng YC, Mozumdar S, Huang L. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev. 2009; 61(9): 721– 731. doi: 10.1016/j.addr.2009.03.003 19328215 PMC3172140 · DOI
  32. [36]Hassani Z, Lemkine GF, Erbacher P, et al. Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels. J Gene Med. 2005; 7(2): 198– 207. doi: 10.1002/jgm.659 15515135 · DOI
  33. [37]Simeoni F, Morris MC, Heitz F, Divita G. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. 2003; 31(11): 2717– 2724. doi: 10.1093/nar/gkg385 12771197 PMC156720 · DOI
  34. [38]Simeoni F, Morris MC, Heitz F, Divita G. Peptide-based strategy for siRNA delivery into mammalian cells BT - RNA silencing: methods and protocols In: Carmichael GG, Totowa NJ, editors. Vol. 309. Humana Press; 2005: 251– 260. doi: 10.1385/1-59259-935-4:251. 15990405 · DOI
  35. [39]Farrow B, Evers BM, Iwamura T, Murillo C, O’Connor KL, Rychahou P. Inhibition of pancreatic cancer cell growth and induction of apoptosis with novel therapies directed against protein kinase A. Surgery. 2003; 134(2): 197– 205. doi: 10.1067/msy.2003.220 12947318 · DOI
  36. [40]Schwarz DS, Hutvágner G, Haley B, Zamore PD. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol Cell. 2002; 10(3): 537– 548. doi: 10.1016/S1097-2765(02)00651-2 12408822 · DOI
  37. [41]Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides. 2008; 18(4): 305– 320. doi: 10.1089/oli.2008.0164 19025401 · DOI
  38. [42]Chiu Y, Rana TM. siRNA function in RNAi: a chemical modification analysis. Rna. 2003; 9: 1034– 1048. doi: 10.1261/rna.5103703.2000 12923253 PMC1370469 · DOI
  39. [43]Hall AHS, Wan J, Shaughnessy EE, Shaw BR, Alexander KA. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res. 2004; 32(20): 5991– 6000. doi: 10.1093/nar/gkh936 15545637 PMC534620 · DOI
  40. [44]Dowler T, Bergeron D, Tedeschi AL, Paquet L, Ferrari N, Damha MJ. Improvements in siRNA properties mediated by 2′-deoxy-2′-fluoro-β-D-arabinonucleic acid (FANA). Nucleic Acids Res. 2006; 34(6): 1669– 1675. doi: 10.1093/nar/gkl033 16554553 PMC1409815 · DOI
  41. [45]Watts JK, Deleavey GF, Damha MJ. Chemically modified siRNA: tools and applications. Drug Discov Today. 2008; 13(19–20): 842– 855. doi: 10.1016/j.drudis.2008.05.007 18614389 · DOI
  42. [46]Xu C, Wang J. Delivery systems for siRNA drug development in cancer therapy. Asian J Pharm Sci. 2015; 10(1): 1– 12. doi: 10.1016/j.ajps.2014.08.011 · DOI
  43. [47]Ghafouri-Fard S, Ghafouri-Fard S. siRNA and cancer immunotherapy. Immunotherapy. 2012; 4(9): 907– 917. doi: 10.2217/imt.12.87 23046235 · DOI
  44. [48]Klippstein R, Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine Nanotechnology Biol Med. 2010; 6(4): 523– 529. doi: 10.1016/j.nano.2010.01.001 20085824 · DOI
  45. [49]Banchereau J, Steinman RM. Dendritic cells and the control of immunology. Nature. 1998; 392: 245– 252. doi: 10.1038/32588 9521319 · DOI
  46. [50]Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Pathology. 2000; 245– 273. doi: 10.1146/annurev.immunol.21.120601.141040 10837059 · DOI
  47. [51]Constantino J, Gomes C, Falcão A, Neves BM, Cruz MT. Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res. 2017; 65(4): 798– 810. doi: 10.1007/s12026-017-8931-1 28660480 · DOI
  48. [52]Verra N, De Jong D, Bex A, et al. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. Eur Urol. 2005; 48(3): 527– 533. doi: 10.1016/j.eururo.2005.03.031 16115526 · DOI
  49. [53]Van Poppel H, Joniau S, Van Gool SW. Vaccine therapy in patients with renal cell carcinoma. Eur Urol. 2009; 55(6): 1333– 1344. doi: 10.1016/j.eururo.2009.01.043 19201522 · DOI
  50. [54]Asemissen AM, Brossart P. Vaccination strategies in patients with renal cell carcinoma. Cancer Immunol Immunother. 2009; 58(7): 1169– 1174. doi: 10.1007/s00262-009-0706-7 19360405 PMC11030192 · DOI
  51. [55]Anguille S, Smits EL, Lion E, Van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014; 15(7): 257– 267. doi: 10.1016/S1470-2045(13)70585-0 24872109 · DOI
  52. [56]Zhang AL, Purath U, Tarner IH, et al. Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood. 2007; 110(7): 2484– 2493. doi: 10.1182/blood-2007-02-076364 17626840 PMC1988958 · DOI
  53. [57]Wang Z, Rao DD, Senzer N, Nemunaitis J. RNA interference and cancer therapy. Pharm Res. 2011: 2983– 2995. doi: 10.1007/s11095-011-0604-5 22009588 · DOI
  54. [58]Li M, Qian H, Ichim TE, et al. Induction of RNA interference in dendritic cells. Immunol Res. 2004; 30(2): 215– 230. doi: 10.1385/IR:30:2:215 15477662 · DOI
  55. [59]Liu S, Liu D, Ji M, et al. An indoleamine 2, 3-dioxygenase siRNA nanoparticle-coated and Trp2-displayed recombinant yeast vaccine inhibits melanoma tumor growth in mice. J Control Release. 2018; 273: 1– 12. doi: 10.1016/j.jconrel.2018.01.013 29355622 · DOI
  56. [60]Filipowicz W, Jaskiewicz L, Kolb FA, Pillai RS. Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol. 2005; 15: 331– 341. doi: 10.1016/j.sbi.2005.05.006 15925505 · DOI
  57. [61]He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7): 522– 531. doi: 10.1038/nrg1379 15211354 · DOI · Paper page
  58. [62]Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009; 457(7228): 426– 433. doi: 10.1038/nature07758 19158789 PMC2702667 · DOI
  59. [63]Tatiparti K, Sau S, Kashaw S, Iyer A. siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials. 2017; 7(4): 77. doi: 10.3390/nano7040077 PMC5408169 28379201 · DOI
  60. [64]Massadeh S, Al Aamery M. Nano-materials for gene therapy: an efficient way in overcoming challenges of gene delivery. J Biosens Bioelectron. 2016; 07(01): 1– 12. doi: 10.4172/2155-6210.1000195 · DOI
  61. [65]Morris KV, Chan SW-L, Jacobsen SE, Looney DJ. Small interfering RNA-induced transcriptional gene silencing in human cells. Cell. 2004; 305(1): 1289– 1293. 15297624
  62. [66]Li J, Xue S, Mao ZW. Nanoparticle delivery systems for siRNA-based therapeutics. J Mater Chem B. 2016; 4(41): 6620– 6639. doi: 10.1039/c6tb01462c 32263517 · DOI
  63. [67]Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 2009; 61(10): 850– 862. doi: 10.1016/j.addr.2009.04.018 19422869 · DOI
  64. [68]Chen M, Du Q, Zhang H-Y, Wahlestedt C, Liang Z. Vector-based siRNA delivery strategies for high-throughput screening of novel target genes. J RNAi Gene Silencing. 2005; 1(1): 5– 11. 19771198 PMC2737198
  65. [69]Lee NS, Dohjima T, Bauer G, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol. 2002; 20(5): 500– 505. doi: 10.1038/nbt0502-500 11981565 · DOI
  66. [70]Moffatt S. siRNA-based nanoparticles for cancer therapy: hurdles and hopes. MOJ Proteomics Bioinforma. 2017; 4(6): 4– 6. doi: 10.15406/mojpb.2016.04.00142 · DOI
  67. [71]Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010; 9(1): 57– 67. doi: 10.1038/nrd3010 20043028 · DOI
  68. [72]Marques JT, Williams BRG. Activation of the mammalian immune system by siRNAs. Nat Biotechnol. 2005; 23: 1399. doi: 10.1038/nbt1161 16273073 · DOI
  69. [73]Alagia A, Eritja R. siRNA and RNAi optimization. Wiley Interdiscip Rev RNA. 2016; 7(3): 316– 329. doi: 10.1002/wrna.1337 26840434 · DOI
  70. [74]Bramsen JB, Pakula MM, Hansen TB, et al. A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res. 2010; 38(17): 5761– 5773. doi: 10.1093/nar/gkq341 20453030 PMC2943616 · DOI
  71. [75]Suter SR, Ball-Jones A, Mumbleau MM, et al. Controlling miRNA-like off-target effects of an siRNA with nucleobase modifications. Org Biomol Chem. 2017; 15(47): 10029– 10036. doi: 10.1039/c7ob02654d 29164215 PMC5734094 · DOI
  72. [76]Alagia A, Jorge AF, Aviñó A, et al. Exploring PAZ/3′-overhang interaction to improve siRNA specificity. A combined experimental and modeling study. Chem Sci. 2018; 9(8): 2074– 2086. doi: 10.1039/c8sc00010g 29719684 PMC5896489 · DOI
  73. [77]Kang HS, Lee D, Li CJ, et al. Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol Ther. 2009; 17(4): 725– 732. doi: 10.1038/mt.2008.298 19156133 PMC2835116 · DOI
  74. [78]Sioud M. Advances in RNA sensing by the immune system: separation of siRNA unwanted effects from RNA interference. Methods Mol Biol. 2010; 629: 33– 52. doi: 10.1007/978-1-60761-657-3_3 20387141 · DOI
  75. [79]Eberle F, Peter M, Richert C, et al. Modifications in small interfering RNA that separate immunostimulation from RNA interference. J Immunol. 2014; 180(5): 3229– 3237. doi: 10.4049/jimmunol.180.5.3229 18292547 · DOI
  76. [80]Slobodkin G, Wilkinson L, Pence C, et al. Versatile cationic lipids for siRNA delivery. J Control Release. 2011; 158(2): 269– 276. doi: 10.1016/j.jconrel.2011.11.006 22100441 · DOI
  77. [83]Love KT, Mahon KP, Christopher G, et al. Correction for Love et al., Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci. 2010; 107(21): 9915. doi: 10.1073/pnas.1005136107 PMC2804742 20080679 · DOI
  78. [85]Grijalvo S, Puras G, Zárate J, et al. Cationic niosomes as non-viral vehicles for nucleic acids: challenges and opportunities in gene delivery. Pharmaceutics. 2019; 11: 2. doi: 10.3390/pharmaceutics11020050 PMC6409589 30678296 · DOI
  79. [87]Derycke A. Liposomes for photodynamic therapy. Adv Drug Deliv Rev. 2003; 56(1): 17– 30. doi: 10.1016/j.addr.2003.07.014 14706443 · DOI
  80. [88]Minko T, Pakunlu RI, Wang Y, Khandare JJ, Saad M. New generation of liposomal drugs for cancer. Anticancer Agents Med Chem. 2014; 6(6): 537– 552. doi: 10.2174/187152006778699095 17100558 · DOI
  81. [89]Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014; 66: 110– 116. doi: 10.1016/j.addr.2013.12.008 24384374 PMC4527165 · DOI
  82. [90]Duchemin A, Evrard B, Piel G, Sanna V, Lechanteur A, Mottet D. Cationic liposomes carrying siRNA: impact of lipid composition on physicochemical properties, cytotoxicity and endosomal escape. Nanomaterials. 2018; 8(5): 270. doi: 10.3390/nano8050270 PMC5977284 29695068 · DOI
  83. [91]Santel A, Aleku M, Keil O, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 2006; 13(16): 1222– 1234. doi: 10.1038/sj.gt.3302777 16625243 · DOI
  84. [92]Aleku M, Schulz P, Keil O, et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 2008; 68(23): 9788– 9798. doi: 10.1158/0008-5472.CAN-08-2428 19047158 · DOI
  85. [93]Wu SY, McMillan NAJ. Lipidic systems for in vivo siRNA delivery. Aaps J. 2009; 11(4): 639– 652. doi: 10.1208/s12248-009-9140-1 19757082 PMC2782074 · DOI
  86. [94]Landen CN, Merritt WM, Mangala LS, et al. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006; 5(12): 1708– 1713. doi: 10.4161/cbt.5.12.3468 17106249 · DOI
  87. [95]Cheng Y, Ji Y. RGD-modified polymer and liposome nanovehicles: recent research progress for drug delivery in cancer therapeutics. Eur J Pharm Sci. 2019; 128: 8– 17. doi: 10.1016/j.ejps.2018.11.023 30471410 · DOI
  88. [96]Mattern-Schain SI, Fisher RK, West PC, et al. Cell mimetic liposomal nanocarriers for tailored delivery of vascular therapeutics. Chem Phys Lipids. 2019; 218: 149– 157. doi: 10.1016/j.chemphyslip.2018.12.009 30582896 · DOI
  89. [98]Ho W, Zhang XQ, Xu X. Biomaterials in siRNA delivery: a comprehensive review. Adv Healthc Mater. 2016; 5(21): 2715– 2731. doi: 10.1002/adhm.201600418 27700013 · DOI
  90. [99]Sood V, Honko AN, MacLachlan I, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010; 375(9729): 1896– 1905. doi: 10.1016/s0140-6736(10)60357-1 20511019 PMC7138079 · DOI
  91. [100]Nikam RR, Gore KR. Journey of siRNA: clinical developments and targeted delivery. Nucleic Acid Ther. 2018; 28(4): 209– 224. doi: 10.1089/nat.2017.0715 29584585 · DOI
  92. [101]Lin PJC, Tam YK. Chapter 9 - controlling protein expression by delivery of RNA therapeutics using lipid nanoparticles In: Filice M, Ruiz-Cabello JBT-NA-N editors. Micro and Nano Technologies. Amsterdam, the Netherlands: Elsevier; 2019: 277– 310. doi: 10.1016/B978-0-12-814470-1.00009-5. · DOI
  93. [102]Zhao J, Weng G, Li J, Zhu J, Zhao J. Polyester-based nanoparticles for nucleic acid delivery. Mater Sci Eng C. 2018; 92: 983– 994. doi: 10.1016/j.msec.2018.07.027 30184828 · DOI
  94. [103]Rozema DB, Lewis DL, Wakefield DH, et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci. 2007; 104(32): 12982LP– 12987. doi: 10.1073/pnas.0703778104 17652171 PMC1941806 · DOI
  95. [104]Wagner E. polymers for sirna delivery: inspired by viruses to be targeted, dynamic, and precise. Acc Chem Res. 2012; 45(7): 1005– 1013. doi: 10.1021/ar2002232 22191535 · DOI
  96. [105]Cheng R, Feng F, Meng F, Deng C, Feijen J, Zhong Z. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J Control Release. 2011; 152(1): 2– 12. doi: 10.1016/j.jconrel.2011.01.030 21295087 · DOI
  97. [106]Farra R, Musiani F, Perrone F, et al. Polymer-mediated delivery of siRNAs to hepatocellular carcinoma: variables affecting specificity and effectiveness. Molecules. 2018; 23(4). doi: 10.3390/molecules23040777 PMC6017305 29597300 · DOI
  98. [107]Parmar RG, Poslusney M, Busuek M, et al. Novel endosomolytic poly(amido amine) polymer conjugates for systemic delivery of siRNA to hepatocytes in rodents and nonhuman primates. Bioconjug Chem. 2014; 25(5): 896– 906. doi: 10.1021/bc400527e 24742200 · DOI
  99. [109]Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm. 2009; 6(3): 659– 668. doi: 10.1021/mp900015y 19267452 · DOI
  100. [110]O’Mahony AM, Godinho BMDC, Ogier J, et al. Click-modified cyclodextrins as nonviral vectors for neuronal siRNA delivery. ACS Chem Neurosci. 2012; 3(10): 744– 752. doi: 10.1021/cn3000372 23077718 PMC3474283 · DOI
  101. [111]Díaz-Moscoso A, Le Gourriérec L, Gómez-García M, et al. Polycationic amphiphilic cyclodextrins for gene delivery: synthesis and effect of structural modifications on plasmid DNA complex stability, cytotoxicity, and gene expression. Chem A Eur J. 2009; 15(46): 12871– 12888. doi: 10.1002/chem.200901149 19834934 · DOI
  102. [112]Miele E, Spinelli GP, Miele E, et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine. 2012; 7: 3637– 3657. doi: 10.2147/IJN.S23696 22915840 PMC3418108 · DOI
  103. [113]Sica G, Chen Z, Wang Z, et al. RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy. Clin Cancer Res. 2013; 19(13): 3416– 3428. doi: 10.1158/1078-0432.ccr-13-0073 23719266 PMC3747783 · DOI
  104. [114]Davis ME, Seligson D, Tolcher A, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464(7291): 1067– 1070. doi: 10.1038/nature08956 20305636 PMC2855406 · DOI
  105. [115]Hovgaard MB, Rahbek UL, Glud SZ, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther. 2006; 14(4): 476– 484. doi: 10.1016/j.ymthe.2006.04.010 16829204 · DOI
  106. [116]Dai K, Winnik F, Qiu X, et al. Low molecular weight chitosan conjugated with folate for siRNA delivery in vitro: optimization studies. Int J Nanomedicine. 2012; 7: 5833. doi: 10.2147/ijn.s35567 23209368 PMC3511191 · DOI
  107. [117]De Smedt SC, Nysten B, Le Duff CS, et al. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency. J Control Release. 2014; 176: 54– 63. doi: 10.1016/j.jconrel.2013.12.026 24389132 · DOI
  108. [118]Kim YK, Minai-Tehrani A, Lee JH, Cho CS, Cho MH, Jiang HL. Therapeutic efficiency of folated poly(ethylene glycol)-chitosan-graft-polyethylenimine-Pdcd4 complexes in H-ras12V mice with liver cancer. Int J Nanomedicine. 2013; 8: 1489– 1498. doi: 10.2147/IJN.S42949 23620665 PMC3630991 · DOI
  109. [119]Kankala RK, Lin XF, Song HF, et al. Supercritical fluid-assisted decoration of nanoparticles on porous microcontainers for codelivery of therapeutics and inhalation therapy of diabetes. ACS Biomater Sci Eng. 2018; 4(12): 4225– 4235. doi: 10.1021/acsbiomaterials.8b00992 33418821 · DOI
  110. [120]Xu P-Y, Kankala RK, Pan Y-J, Yuan H, Wang S-B, Chen A-Z. Overcoming multidrug resistance through inhalable siRNA nanoparticles-decorated porous microparticles based on supercritical fluid technology. Int J Nanomedicine. 2018; 13: 4685– 4698. doi: 10.2147/IJN.S169399 30154654 PMC6103603 · DOI
  111. [121]Wang S-B, Chen A-Z, Tang N, Su X-Q, Kang Y-Q. Preparation and antitumor effect evaluation of composite microparticles co-loaded with siRNA and paclitaxel by a supercritical process. J Mater Chem B. 2015; 3(31): 6439– 6447. doi: 10.1039/c5tb00715a 32262552 · DOI
  112. [122]Kankala RK, Chen B-Q, Liu C-G, Tang H-X, Wang S-B, Chen A-Z. Solution-enhanced dispersion by supercritical fluids: an ecofriendly nanonization approach for processing biomaterials and pharmaceutical compounds. Int J Nanomedicine. 2018; 13: 4227– 4245. doi: 10.2147/IJN.S166124 30087558 PMC6061406 · DOI
  113. [123]Licciardi M, Li Volsi A, Sardo C, Mauro N, Cavallaro G, Giammona G. Inulin-ethylenediamine coated SPIONs magnetoplexes: a promising tool for improving siRNA delivery. Pharm Res. 2015; 32(11): 3674– 3687. doi: 10.1007/s11095-015-1726-y 26085039 · DOI
  114. [124]Sardo C, Farra R, Licciardi M, et al. Development of a simple, biocompatible and cost-effective Inulin-Diethylenetriamine based siRNA delivery system. Eur J Pharm Sci. 2015; 75: 60– 71. doi: 10.1016/j.ejps.2015.03.021 25845631 · DOI
  115. [125]Sardo C, Craparo EF, Porsio B, Giammona G, Cavallaro G. Improvements in rational design strategies of inulin derivative polycation for siRNA delivery. Biomacromolecules. 2016; 17(7): 2352– 2366. doi: 10.1021/acs.biomac.6b00281 27238382 · DOI
  116. [126]Aigner A. Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotechnol. 2006; 2006: 1– 15. doi: 10.1155/JBB/2006/71659 PMC1559929 17057369 · DOI
  117. [127]Akhtar S, Benter IF. Review series nonviral delivery of synthetic siRNAs in vivo. J Clin Invest. 2007; 117(12): 3623– 3632. doi: 10.1172/JCI33494.following 18060020 PMC2096447 · DOI
  118. [128]Judge A, Fritz EA, Phelps JR, et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis. 2006; 193(12): 1650– 1657. doi: 10.1086/504267 16703508 PMC7110204 · DOI
  119. [129]Bai A, Chen J, Filip L, Nguyen T, Ge Q, Eisen HN. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci. 2004; 101(23): 8676– 8681. doi: 10.1073/pnas.0402486101 15173599 PMC423254 · DOI
  120. [130]Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2004; 12: 461. doi: 10.1038/sj.gt.3302425 15616603 · DOI
  121. [131]Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev. 2007; 59(2–3): 164– 182. doi: 10.1016/j.addr.2007.03.010 17481774 · DOI
  122. [132]Pandey AP, Sawant KK. Polyethylenimine: A versatile, multifunctional non-viral vector for nucleic acid delivery. Mater Sci Eng C. 2016; 68: 904– 918. doi: 10.1016/j.msec.2016.07.066 27524093 · DOI
  123. [133]Wang J, Lu Z, Wientjes MG, Au JL-S. Delivery of siRNA therapeutics: barriers and carriers. Aaps J. 2010; 12(4): 492– 503. doi: 10.1208/s12248-010-9210-4 20544328 PMC2977003 · DOI
  124. [134]Fornaguera C, Grijalvo S, Galán M, et al. Novel non-viral gene delivery systems composed of carbosilane dendron functionalized nanoparticles prepared from nano-emulsions as non-viral carriers for antisense oligonucleotides. Int J Pharm. 2015; 478(1): 113– 123. doi: 10.1016/j.ijpharm.2014.11.031 25448573 · DOI
  125. [135]Khan A, Benboubetra M, Sayyed PZ, et al. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J Drug Target. 2004; 12(6): 393– 404. doi: 10.1080/10611860400003858 15545089 · DOI
  126. [136]Svenson S, Case RI, Cole RO, et al. Tumor selective silencing using an RNAi-conjugated polymeric nanopharmaceutical. Mol Pharm. 2016; 13(3): 737– 747. doi: 10.1021/acs.molpharmaceut.5b00608 26835715 · DOI
  127. [137]Byeon Y, Lee J-W, Choi WS, et al. CD44-targeting PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer. Cancer Res. 2018; 78(21): 6247LP– 6256. doi: 10.1158/0008-5472.CAN-17-3871 30115698 · DOI
  128. [138]Winkler J. Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides. Ther Deliv. 2011; 2(7): 891– 905. doi: 10.4155/tde.11.56 22318893 PMC3272463 · DOI
  129. [139]Kaneshiro TL, Lu ZR. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials. 2009; 30(29): 5660– 5666. doi: 10.1016/j.biomaterials.2009.06.026 19595449 · DOI
  130. [140]Bhatia S, Zhu H, Birjiniuk A, et al. Functional delivery of siRNA in mice using dendriworms. ACS Nano. 2009; 3(9): 2495– 2504. doi: 10.1021/nn900201e 19673534 PMC2828182 · DOI
  131. [141]Zhou J, Shum KT, Burnett JC, Rossi JJ. Nanoparticle-based delivery of RNAi therapeutics: progress and challenges. Pharmaceuticals. 2013; 6(1): 85– 107. doi: 10.3390/ph6010085 23667320 PMC3649006 · DOI
  132. [142]Cheung W, Pontoriero F, Taratula O, Chen AM, He H. DNA and carbon nanotubes as medicine. Adv Drug Deliv Rev. 2010; 62(6): 633– 649. doi: 10.1016/j.addr.2010.03.007 20338203 · DOI
  133. [143]Lynn Kirkpatrick D, Weiss M, Naumov A, Bartholomeusz G, Bruce Weisman R, Gliko O. Carbon nanotubes: solution for the therapeutic delivery of siRNA? Materials (Basel). 2012; 5(2): 278– 301. doi: 10.3390/ma5020278 28817045 PMC5448908 · DOI
  134. [144]Zhang Z, Yang X, Zhang Y, et al. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res. 2006; 12(16): 4933– 4939. doi: 10.1158/1078-0432.CCR-05-2831 16914582 · DOI
  135. [145]Jiang Y, Huo S, Hardie J, Liang X-J, Rotello VM. Progress and perspective of inorganic nanoparticle-based siRNA delivery systems. Expert Opin Drug Deliv. 2016; 13(4): 547– 559. doi: 10.1517/17425247.2016.1134486 26735861 PMC4914043 · DOI
  136. [146]Gindy ME, Prud’homme RK. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin Drug Deliv. 2009; 6(8): 865– 878. doi: 10.1517/17425240902932908 19637974 · DOI · Paper page
  137. [147]Sangvanich T, Bejan D, Gu S, Yantasee W, Reda M, Ngamcherdtrakul W. Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery. Int J Nanomedicine. 2018; 13: 4015– 4027. doi: 10.2147/ijn.s164393 30022824 PMC6045907 · DOI
  138. [148]Tiash S, Kamaruzman NIB, Chowdhury EH. Carbonate apatite nanoparticles carry siRNA(s) targeting growth factor receptor genes egfr1 and erbb2 to regress mouse breast tumor. Drug Deliv. 2017; 24(1): 1721– 1730. doi: 10.1080/10717544.2017.1396385 29119846 PMC8240997 · DOI
  139. [149]Courty J, Latorre A, Villanueva A, et al. Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery. Breast Cancer Res. 2015; 17(1): 1– 17. doi: 10.1186/s13058-015-0576-1 25968050 PMC4451751 · DOI
  140. [150]Cai D, Long R, Liu Y, et al. Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro. Int J Nanomedicine. 2018; 13: 8269– 8279. doi: 10.2147/ijn.s180503 30584299 PMC6289231 · DOI
  141. [151]Wu Z, Shen J, Zhang L-M, et al. Magnetic cationic amylose nanoparticles used to deliver survivin-small interfering RNA for gene therapy of hepatocellular carcinoma in vitro. Nanomaterials. 2017; 7(5): 110. doi: 10.3390/nano7050110 PMC5449991 28492491 · DOI
  142. [152]Roca M, Aj H. Probing cells with noble metal nanoparticle aggregates. Nanomedicine. 2008; 3(4): 555– 565. doi: 10.2217/17435889.3.4.555 18694317 · DOI
  143. [153]Xu ZP, Zeng QH, Lu GQ, Yu AB. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Eng Sci. 2006; 61(3): 1027– 1040. doi: 10.1016/j.ces.2005.06.019 · DOI
  144. [154]Wong JKL, Habib N, Seifalian AM, Mohseni R, Hamidieh AA, MacLaren RE. Will nanotechnology bring new hope for gene delivery? Trends Biotechnol. 2017; 35(5): 434– 451. doi: 10.1016/j.tibtech.2016.12.009 28108036 · DOI
  145. [155]Mendes R, Fernandes AR, Baptista PV. Gold nanoparticle approach to the selective delivery of gene silencing in cancer-The case for combined delivery? Genes (Basel). 2017; 8(3): 94. doi: 10.3390/genes8030094 PMC5368698 28257109 · DOI
  146. [156]Hou W, Wei P, Kong L, Guo R, Wang S, Shi X. Partially PEGylated dendrimer-entrapped gold nanoparticles: A promising nanoplatform for highly efficient DNA and siRNA delivery. J Mater Chem B. 2016; 4(17): 2933– 2943. doi: 10.1039/c6tb00710d 32262971 · DOI
  147. [157]Tokatlian T, Segura T. siRNA applications in nanomedicine. Wiley Interdiscip Rev Nanomedicine Nanobiotechnology. 2010; 2(3): 305– 315. doi: 10.1002/wnan.81 20135697 PMC4104279 · DOI
  148. [158]Benitez-Del-Castillo JM, Moreno-Montañés J, Jiménez-Alfaro I, et al. Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease. Investig Ophthalmol Vis Sci. 2016; 57(14): 6447– 6454. doi: 10.1167/iovs.16-20303 27893109 · DOI
  149. [159]Perales JC, Marquez VE, Eritja R, Ocampo SM, Terrazas M. Effect of north bicyclo[3.1.0]hexane 2′-Deoxy-pseudosugars on RNA Interference: a novel class of siRNA modification. ChemBioChem. 2011; 12(7): 1056– 1065. doi: 10.1002/cbic.201000791 21452187 · DOI
  150. [160]Grijalvo S, Alagia A, Jorge AF, Eritja R. Covalent strategies for targeting messenger and non-coding RNAs: an updated review on siRNA, miRNA and antimiR conjugates. Genes (Basel). 2018; 9: 2. doi: 10.3390/genes9020074 PMC5852570 29415514 · DOI
  151. [161]Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004; 432(7014): 173– 178. doi: 10.1038/nature03121 15538359 · DOI
  152. [162]Manoharan M, Andree C, Amaya P, et al. Identification of siRNA delivery enhancers by a chemical library screen. Nucleic Acids Res. 2015; 43(16): 7984– 8001. doi: 10.1093/nar/gkv762 26220182 PMC4652771 · DOI
  153. [164]Meyers RE, Weiss GJ, Clausen VA, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013; 3(4): 406– 417. doi: 10.1158/2159-8290.cd-12-0429 23358650 · DOI
  154. [165]Donahoe JS, Nahrendorf M, Langer R, et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol. 2012; 7(6): 389– 393. doi: 10.1038/nnano.2012.73 22659608 PMC3898745 · DOI
  155. [166]Salvans C, Brun-Heath I, Ivani I, et al. Rational design of novel N-alkyl-N capped biostable RNA nanostructures for efficient long-term inhibition of gene expression. Nucleic Acids Res. 2016; 44(9): 4354– 4367. doi: 10.1093/nar/gkw169 26975656 PMC4872095 · DOI
  156. [167]He C, Weizmann Y, Lin W, Liu D, Gannett TR, Chen G. Enzymatic synthesis of periodic DNA nanoribbons for intracellular pH sensing and gene silencing. J Am Chem Soc. 2015; 137(11): 3844– 3851. doi: 10.1021/ja512665z 25622178 · DOI
  157. [168]Ruan W, Zheng M, An Y, et al. DNA nanoclew templated spherical nucleic acids for siRNA delivery. Chem Commun. 2018; 54(29): 3609– 3612. doi: 10.1039/c7cc09257a 29570195 · DOI
  158. [169]Jorge AF, Eritja R. Overview of DNA self-assembling: progresses in biomedical applications. Pharmaceutics. 2018; 10: 4. doi: 10.3390/pharmaceutics10040268 PMC6320858 30544945 · DOI
  159. [170]Li H, Wang L, Fan C, Gu H, Hu Q. DNA nanotechnology-enabled drug delivery systems. Chem Rev. 2018. doi: 10.1021/acs.chemrev.7b00663 29465222 · DOI
  160. [171]Ni Z, Hui P. Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica. 2009; 223(6): 401– 410. doi: 10.1159/000228926 19622904 · DOI
  161. [172]Chakraborty C, Sharma AR, Sharma G, Doss CGP, Lee S-S. Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine. Mol Ther Nucleic Acids. 2017; 8: 132– 143. doi: 10.1016/j.omtn.2017.06.005 28918016 PMC5496203 · DOI
  162. [173]Xin Y, Huang M, Guo WW, Huang Q, Zhang L, Jiang G. Nano-based delivery of RNAi in cancer therapy. Mol Cancer. 2017; 16(1): 1– 9. doi: 10.1186/s12943-017-0683-y 28754120 PMC5534073 · DOI
  163. [174]Shim MS, Wong S, Kwon YJ. SiRNA as a conventional drug in the clinic? Challenges and current technologies. Drug Discov Today Technol. 2012; 9(2): e167– e173. doi: 10.1016/j.ddtec.2012.01.003 24064278 · DOI
  164. [175]Ferrari M. Vectoring siRNA therapeutics into the clinic. Nat Rev Clin Oncol. 2010; 7: 485. doi: 10.1038/nrclinonc.2010.131 20798696 · DOI
  165. [176]Santel A, Kaufmann J, Strumberg D, et al. First-in-human phase I Study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol. 2014; 32(36): 4141– 4148. doi: 10.1200/jco.2013.55.0376 25403217 · DOI
  166. [177]Tabernero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013; 3(4): 406LP– 417. doi: 10.1158/2159-8290.CD-12-0429 23358650 · DOI
  167. [178]Tolcher AW, Papadopoulos KP, Patnaik A, et al. Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors. J Clin Oncol. 2015; 33(15_suppl): 11006. doi: 10.1200/jco.2015.33.15_suppl.11006 · DOI
  168. [179]Wagner MJ, Sood AK, Lopez-Berestein G, et al. Preclinical mammalian safety studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol Cancer Ther. 2017; 16(6): 1114– 1123. doi: 10.1158/1535-7163.mct-16-0541 28265009 PMC5457703 · DOI
  169. [181]Mahmoodzadeh H, Moazzen F, Mehmandoost N, et al. Cloning and expression of C2 and V Domains of ALCAM Protein in E. coli BL21 (DE3). Clin Microbiol Open Access. 2017; 06(01): 1– 6. doi: 10.4172/2327-5073.1000271 · DOI
  170. [183]Dana H. CD166 as a stem cell marker? A potential target for therapy colorectal cancer? J Stem Cell Res Ther. 2017; 1(6): 6– 9. doi: 10.15406/jsrt.2016.01.00041 · DOI

Cited by

Sorted by citations

See all 221

Metadata

Authors
Mahmoodi Chalbatani, G., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R., Logsdon, C. D., Memari, F., Miri, S. R., Rezvani Rad, M., & Marmari, V.
Venue
International Journal of Nanomedicine
Publisher
Informa UK Limited
Published
2019-05
Volume
Volume 14
Pages
3111-3128
ISSN
1178-2013
DOI
10.2147/ijn.s200253
PMC
PMC6504672
Cited by
221
References
12
Language
en
Licence
creativecommons.org/licenses/by-nc/3.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review